Articles From: Bio-Rad to Report Fourth-Quarter and Full-Year 2012 Financial Results Tuesday, February 26, 2013 to BioCryst to Present at Two Upcoming Investor Conferences


2013/1/29
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=979219&ProfileId=051205&sourceType=1 HERCULES, CA --
Sign-up for Bio-Rad to Report Fourth-Quarter and Full-Year 2012 Financial Results Tuesday, February 26, 2013 investment picks
2013/6/5
ELMWOOD PARK, N.J., June 5, 2013 (GLOBE NEWSWIRE) -- Bio-Reference Laboratories, Inc (Nasdaq:BRLI) announced today that Marc D.
Sign-up for Bio-Reference Laboratories, Inc to Speak at William Blair & Company's 33rd Annual Growth Stock Conference investment picks
2013/5/30
ELMWOOD PARK, N.J., May 30, 2013 (GLOBE NEWSWIRE) -- Bio-Reference Laboratories, Inc. (Nasdaq:BRLI) announced today it plans to issue earnings results for the second quarter of fiscal 2013 before the open of market trading on Thursday, June 6, 2013.
Sign-up for Bio-Reference Laboratories, Inc. Announces Earnings Date for Second Quarter for Fiscal Year 2013 investment picks
2013/2/28
ELMWOOD PARK, N.J., Feb.
Sign-up for Bio-Reference Laboratories, Inc. Announces Strong Growth Resulting in Record First Quarter Revenue and Earnings investment picks
2013/4/12
ELMWOOD PARK, N.J., April 12, 2013 (GLOBE NEWSWIRE) -- Bio-Reference Laboratories, Inc. (Nasdaq:BRLI) strongly denounced and denied the allegations of a complaint that has been filed against the Company in the Superior Court of New Jersey by an apparently disgruntled, former employee.
Sign-up for Bio-Reference Laboratories, Inc. Responds to an Employee Wrongful Termination Suit Filed Against it as Baseless and Without Merit investment picks
2013/5/8
ELMWOOD PARK, N.J., May 8, 2013 (GLOBE NEWSWIRE) -- Bio-Reference Laboratories, Inc. (Nasdaq:BRLI) announced today that Marc D.
Sign-up for Bio-Reference Laboratories, Inc. to Speak at the Bank of America Merrill Lynch Health Care Conference investment picks
2013/2/27
ELMWOOD PARK, N.J., Feb.
Sign-up for Bio-Reference Laboratories, Inc. Will Offer Non-Invasive Prenatal Testing (NIPT) From Natera investment picks
2013/6/10
MINNEAPOLIS, MN , June 10, 2013 /PRNewswire/ - BioAmber Inc. ("BioAmber") (NYSE: BIOA) announced today that the French Autorité des marchés financiers (AMF) approved BioAmber's prospectus for admission of its common stock to listing and trading on the Professional Segment of NYSE Euronext Paris, and has granted visa number 13-265, dated June 10, 2013 , on the prospectus.
Sign-up for BioAmber Inc. Announces Admission to NYSE Euronext Paris investment picks
2013/6/10
Sign-up for BioAmber Inc. Announces Admission to NYSE Euronext Paris investment picks
2013/5/14
BioAmber Inc. Announces Closing of Initial Public Offering Canada NewsWire MINNEAPOLIS , MN, May 14, 2013 /CNW Telbec/ - BioAmber Inc. ("BioAmber") (NYSE: BIOA.U) , announced today the closing of its initial public offering of 8,000,000 units consisting of one share of common stock and one warrant to purchase half of one share of common stock at $10.00 per unit, before underwriting discounts and commissions.
Sign-up for BioAmber Inc. Announces Closing of Initial Public Offering investment picks
2013/5/14
MINNEAPOLIS, MN , May 14, 2013 /PRNewswire/ - BioAmber Inc. ("BioAmber") (NYSE: BIOA.U) , announced today the closing of its initial public offering of 8,000,000 units consisting of one share of common stock and one warrant to purchase half of one share of common stock at $10.00 per unit, before underwriting discounts and commissions.
Sign-up for BioAmber Inc. Announces Closing of Initial Public Offering investment picks
2013/6/3
BioAmber Inc. Announces Separate Trading of Common Stock and Warrants Canada NewsWire About BioAmber Inc. BioAmber is a next generation chemicals company.
Sign-up for BioAmber Inc. Announces Separate Trading of Common Stock and Warrants investment picks
2013/6/3
MINNEAPOLIS, MN , June 3, 2013 /PRNewswire/ - BioAmber Inc. ("BioAmber") (NYSE: BIOA.U) , announced today that commencing on June 10, 2013 , the common stock and warrants comprising BioAmber's units will as previously disclosed begin trading separately on the New York Stock Exchange ("NYSE") under the symbols "BIOA" and "BIOA.WS", respectively.
Sign-up for BioAmber Inc. Announces Separate Trading of Common Stock and Warrants investment picks
2013/2/4
Bioanalytical Systems, Inc. (NASDAQ:BASI) will release financial results for the first quarter ended December 31, 2012 at approximately 8:30 a.m. EST on Thursday, February 14, 2013.
Sign-up for Bioanalytical Systems to Release First Quarter Results Thursday, February 14, 2013 investment picks
2013/5/9
Bioanalytical Systems, Inc. (NASDAQ:BASI) will release financial results for the second quarter ended March 31, 2013 at approximately 8:30 a.m. EDT on Wednesday, May 15, 2013.
Sign-up for Bioanalytical Systems to Release Second Quarter Results Wednesday, May 15, 2013; Conference Call & Webcast Set For 11:00 a.m. EDT investment picks
2013/4/3
TEL AVIV, Israel , April 3, 2013 /PRNewswire/ -- Bioassociate has released valuation coverage on RedHill Biopharma, Ltd.
Sign-up for Bioassociate Announces Valuation Report on RedHill Biopharma, Ltd. investment picks
2013/3/14
BioClinica ® , Inc., (NASDAQ: BIOC) , a global provider of clinical trial management services, announced today that JLL Partners and Ampersand Capital Partners, two leading middle market private equity firms, have completed their acquisition of BioClinica and CoreLab Partners and have combined the two companies under the name BioClinica.
Sign-up for BioClinica and CoreLab Partners Are One investment picks
2013/2/6
BioClinica ® , Inc. (NASDAQ: BIOC) , a leading global provider of clinical trial management solutions, today announced its financial results for the fourth quarter and full year ended December 31, 2012.
Sign-up for BioClinica Announces Fourth Quarter and Full Year 2012 Financial Results investment picks
2013/1/30
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of BioClinica, Inc. (“BioClinica”) (Nasdaq: BIOC) to a holding company controlled by JLL Partners, Inc. for shareholders.
Sign-up for BioClinica Shareholder Alert: Briscoe Law Firm and Powers Taylor, LLP Investigate Sale to JLL Partners investment picks
2013/2/4
BioClinica, Inc. (NASDAQ: BIOC) , a leading global provider of clinical trial management solutions, will release its financial results for the fourth quarter and year ended December 31, 2012 on Wednesday, February 6, 2013.
Sign-up for BioClinica to Release Fourth Quarter and Year-End 2012 Financial Results on February 6, 2013 investment picks
2013/2/21
BioClinica®, Inc. (NASDAQ: BIOC) , a leading global provider of clinical trial management solutions, and JLL Partners, Inc., a leading private equity investment firm, today announced that early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has been granted in connection with the pending acquisition by BC Acquisition Corp., a wholly-owned subsidiary of BioCore Holdings, Inc., of BioClinica for $7.25 per share in cash.
Sign-up for BioClinica, Inc. and JLL Partners, Inc. Announce Early Termination of Hart-Scott-Rodino Act Waiting Period investment picks
2013/3/12
BioClinica®, Inc. (NASDAQ: BIOC) , a leading global provider of clinical trial management solutions, and JLL Partners, Inc. (“JLL”), a leading private equity investment firm, today announced the successful completion of the tender offer by BC Acquisition Corp.
Sign-up for BioClinica, Inc. and JLL Partners, Inc. Announce Successful Completion of Tender Offer investment picks
2013/1/30
Glancy Binkow & Goldberg LLP announces that it is investigating potential claims against the Board of Directors of BioClinica, Inc. (“BioClinica” or the “Company”) (NASDAQ: BIOC) related to the proposed acquisition of the Company by JLL Partners, Inc. The transaction is valued at approximately $123 million or $7.25 per share.
Sign-up for BioClinica, Inc. Board of Directors Under Investigation for Potential Breaches of Fiduciary Duty by Glancy Binkow & Goldberg LLP investment picks
2013/3/25
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX4161 in healthy volunteers.
Sign-up for BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary Angioedema investment picks
2013/4/16
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has completed its Type C meeting regarding intravenous (i.v.) peramivir with the U.S. Food & Drug Administration (FDA) and has received final meeting minutes.
Sign-up for BioCryst Pharmaceuticals Completes Peramivir Type C Meeting investment picks
2013/4/1
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it received a preliminary comment letter from the U.S. Food & Drug Administration (FDA) that outlines a pathway by which BioCryst could file a New Drug Application (NDA) seeking regulatory approval of intravenous (i.v.) peramivir .
Sign-up for BioCryst Pharmaceuticals Provides Update Regarding Peramivir investment picks
2013/5/7
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2013.
Sign-up for BioCryst Provides Corporate Update and Reports First Quarter 2013 Financial Results investment picks
2013/4/23
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2013 financial results will be released on Tuesday, May 7, 2013.
Sign-up for BioCryst to Announce First Quarter 2013 Financial Results May 7 investment picks
2013/2/5
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its fourth quarter and full year 2012 financial results will be released on Tuesday, February 19, 2013.
Sign-up for BioCryst to Announce Fourth Quarter & 2012 Financial Results on February 19, 2013 investment picks
2013/5/9
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company’s clinical programs at the following investor conferences: Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm .
Sign-up for BioCryst to Present at Two Upcoming Investor Conferences investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Bio-Rad to Report Fourth-Quarter and Full-Year 2012 Financial Results Tuesday, February 26, 2013 to BioCryst to Present at Two Upcoming Investor Conferences
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity